Roeback J R, Hla K M, Chambless L E, Fletcher R H
School of Public Health, Department of Epidemiology, University of North Carolina, Chapel Hill 27599.
Ann Intern Med. 1991 Dec 15;115(12):917-24. doi: 10.7326/0003-4819-115-12-917.
To determine the efficacy of glucose tolerance factor (GTF)-chromium for increasing serum levels of high-density lipoprotein (HDL) cholesterol in patients taking beta-blockers.
Randomized, double-blind, placebo-controlled trial.
Mixed primary and referral-based outpatient clinic at a university-affiliated VA Medical Center.
Referred sample of 72 men receiving beta-blockers, mainly for hypertension. Sixty-three patients (88%) completed the study.
Current medications, including beta-blockers, were continued. During the 8-week treatment phase, patients in the chromium group received a total daily dose of 600 micrograms of biologically active chromium divided into three equal doses; control patients received a placebo of identical appearance and taste.
Serum levels of total cholesterol and HDL cholesterol were measured.
Mean baseline levels of HDL and total cholesterol (+/- SD) were 0.93 +/- 0.28 mmol/L and 6.0 +/- 1.0 mmol/L (36 +/- 11.1 mg/dL and 232 +/- 38.5 mg/dL), respectively. The difference between groups in adjusted mean change in HDL cholesterol levels, accounting for baseline HDL cholesterol levels, age, weight change, and baseline total cholesterol levels, was 0.15 mmol/L (5.8 mg/dL) (P = 0.01) with a 95% Cl showing that the treatment effect was greater than +0.04 mmol/L (+1.4 mg/dL). Mean total cholesterol, triglycerides and body weight did not change significantly during treatment for either group. Compliance as measured by pill count was 85%, and few side effects were reported. Two months after the end of treatment, the between-group difference in adjusted mean change from baseline to end of post-treatment follow-up was -0.003 mmol/L (-0.1 mg/dL).
Two months of chromium supplementation resulted in a clinically useful increase in HDL cholesterol levels in men taking beta-blockers.
确定葡萄糖耐量因子(GTF)-铬对提高服用β受体阻滞剂患者血清高密度脂蛋白(HDL)胆固醇水平的疗效。
随机、双盲、安慰剂对照试验。
大学附属退伍军人医疗中心的混合初级和转诊门诊。
72名主要因高血压而接受β受体阻滞剂治疗的男性患者样本。63名患者(88%)完成了研究。
继续服用包括β受体阻滞剂在内的当前药物。在为期8周的治疗阶段,铬组患者每日总剂量为600微克生物活性铬,分三次等量服用;对照患者服用外观和味道相同的安慰剂。
测量血清总胆固醇和HDL胆固醇水平。
HDL和总胆固醇的平均基线水平(±标准差)分别为0.93±0.28毫摩尔/升和6.0±1.0毫摩尔/升(36±11.1毫克/分升和232±38.5毫克/分升)。考虑到基线HDL胆固醇水平、年龄、体重变化和基线总胆固醇水平,两组间HDL胆固醇水平调整后平均变化的差异为0.15毫摩尔/升(5.8毫克/分升)(P = 0.01),95%可信区间显示治疗效果大于+0.04毫摩尔/升(+1.4毫克/分升)。两组患者在治疗期间平均总胆固醇、甘油三酯和体重均无显著变化。通过药片计数测量的依从性为85%,报告的副作用很少。治疗结束两个月后,从基线到治疗后随访结束调整后平均变化的组间差异为-0.003毫摩尔/升(-0.1毫克/分升)。
两个月的铬补充剂治疗使服用β受体阻滞剂的男性患者HDL胆固醇水平出现了临床上有益的升高。